Financials

News Discussions Technicals Seasonals

Cash from financing activities of PRESTIGE BIOPHARMA LIMITED KDR

Annual data

2019

2020

2021

2022

2023

2024

TTM

‪‪−160.00 B‬‬

‪0.00‬

‪‪160.00 B‬‬

‪‪320.00 B‬‬

‪‪480.00 B‬‬

Period

Value

Change

Change %

TTM

—

—

—

2024

‪‪−1.47 B‬‬

‪‪−54.69 B‬‬

‪−102.75‬%

2023

‪‪53.22 B‬‬

+‪‪57.73 B‬‬

—

2022

‪‪−4.51 B‬‬

‪‪−458.99 B‬‬

‪−100.99‬%

2021

‪‪454.48 B‬‬

+‪‪388.32 B‬‬

+‪586.87‬%

2020

‪‪66.17 B‬‬

+‪‪26.43 B‬‬

+‪66.51‬%

2019

Quarterly data

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q1 '25

Q2 '25

‪‪−15.00 B‬‬

‪0.00‬

‪‪15.00 B‬‬

‪‪30.00 B‬‬

‪‪45.00 B‬‬

Period

Value

Change

Change %

Q2 '25

‪‪31.57 B‬‬

+‪‪11.75 B‬‬

+‪59.28‬%

Q1 '25

‪‪19.82 B‬‬

+‪‪19.70 B‬‬

+‪‪16.42 K‬‬%

Q3 '24

‪‪119.96 M‬‬

+‪‪3.33 B‬‬

—

Q2 '24

‪‪−3.21 B‬‬

‪‪−5.34 B‬‬

‪−250.62‬%

Q1 '24

‪‪2.13 B‬‬

‪‪−8.56 B‬‬

‪−80.06‬%

Q4 '23

‪‪10.69 B‬‬

‪‪−32.59 B‬‬

‪−75.29‬%

Q3 '23

‪‪43.28 B‬‬

+‪‪43.47 B‬‬

—

Q2 '23

‪‪−186.16 M‬‬

+‪‪477.21 M‬‬

+‪71.94‬%

Q1 '23

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21